A new retrospective cohort study conducted in Dubai shows that the antiviral nirmatrelvir plus ritonavir, sold as Paxlovid, ...

Aycock was diagnosed with COVID-19 and got a prescription for Paxlovid, but it was going to cost him $1,400. Aycock said he tried his best to get his hands on the prescription. I ...

At Shionogi, a Japanese pharmaceutical company, executives pointed out that COVID is still flaring in Japan. In Japan, ...

COVID-19 clinical rebound following treatment with nirmatrelvir-ritonavir (Paxlovid) was generally mild and associated with favorable outcomes.

Pfizer reported higher-than-expected profits driven by strong Paxlovid sales, offsetting a decline in COVID vaccine sales.

A boost from COVID-19 treatment sales helped bush Pfizer to a better-than-expected third quarter and higher forecast for the ...

Amid a looming standoff with activist investor Starboard Value, Pfizer fought back against accusations of underperforming by delivering double digit revenue growth over the third quarter and notchi | ...

Pfizer PFE reported third-quarter 2024 adjusted earnings per share of $1.06, which crushed the Zacks Consensus Estimate of 64 ...

On Oct. 29, Pfizer PFE announced third-quarter results, beating estimates for earnings as well as sales. Revenues rose 32% on ...

MEDICAL CARE CAN BE EXPENSIVE, AS WE ALL KNOW, BUT THAT’S WHERE HEALTH INSURANCE IS SUPPOSED TO COME IN TO ALLEVIATE THE COST ...

NEW YORK — A boost from Covid-19 treatment sales helped bush Pfizer to a better-than-expected third quarter and higher ...

On Tuesday, Pfizer Inc. (NYSE:PFE) reported third-quarter adjusted EPS of $1.06, a turnaround from loss of 17 cents a year ...